Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures

Cancers

Lieve Brochez¹  Nora Sundahl¹  Annelies Demeyer¹  Karel Decaestecker¹  Piet Ost¹  Vibeke Kruse¹  Sylvie Rottey¹  Mathieu Spaas¹  Yvan Saeys¹  Jo Van Dorpe¹  Annabel Meireson¹  SimonJ. Tavernier²  Filomeen Haerynck²  Liesbeth Ferdinande³  Benjamin Hennart⁴  Delphine Allorge⁴  Sofie Van Gassen⁵ 

[1] Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium;Centre for Primary Immunodeficiency Ghent, Primary Immune Deficiency Research Lab, Department of Internal Medicine and Pediatrics, Jeffrey Modell Diagnosis and Research Centre, Ghent University Hospital, 9000 Ghent, Belgium;Department of Pathology, Ghent University Hospital, 9000 Ghent, Belgium;Unité Fonctionnelle de Toxicologie, CHU Lille, F-59000 Lille, France;VIB Center for Inflammation Research, Unit of Data Mining and Modeling for Biomedicine, 9000 Ghent, Belgium;

关键词: immunotherapy;    anti-PD-1;    melanoma;    urothelial cancer;    immune monitoring;    blood biomarkers;   

DOI  :  10.3390/cancers13112630

来源: DOAJ

【 摘 要 】

(1) Background: Blockade of the PD-1/PD-L1 pathway has revolutionized the oncology field in the last decade. However, the proportion of patients experiencing a durable response is still limited. In the current study, we performed an extensive immune monitoring in patients with stage III/IV melanoma and stage IV UC who received anti-PD-1 immunotherapy with SBRT. (2) Methods: In total 145 blood samples from 38 patients, collected at fixed time points before and during treatment, were phenotyped via high-parameter flow cytometry, luminex assay and UPLC-MS/MS. (3) Results: Baseline systemic immunity in melanoma and UC patients was different with a more prominent myeloid compartment and a higher neutrophil to lymphocyte ratio in UC. Proliferation (Ki67⁺) of CD8⁺ T-cells and of the PD-1⁺/PD-L1⁺ CD8⁺ subset at baseline correlated with progression free survival in melanoma. In contrast a higher frequency of PD-1/PD-L1 expressing non-proliferating (Ki67⁻) CD8⁺ and CD4⁺ T-cells before treatment was associated with worse outcome in melanoma. In UC, the expansion of Ki67⁺ CD8⁺ T-cells and of the PD-L1⁺ subset relative to tumor burden correlated with clinical outcome. (4) Conclusion: This study reveals a clearly different immune landscape in melanoma and UC at baseline, which may impact immunotherapy response. Signatures of proliferation in the CD8⁺ T-cell compartment prior to and early after anti-PD-1 initiation were positively correlated with clinical outcome in both cohorts. PD-1/PD-L1 expression on circulating immune cell subsets seems of clinical relevance in the melanoma cohort.

【 授权许可】

Unknown